Download by
Scanning QR Code
No Stock Yet
No Data
01877.HK appoints Dr. Zou Jianjun as Executive Director
Resolution No. 11 appointing Dr. Zou Jianjun as Executive Director was approved at the 2021 annual general meeting of the company held on June 29th, 2022, according to the announcement of 01877.HK. The appointment of Dr. Zou as an executive director has taken effect on the date of the annual general meeting (i.e. 29 June 2022).
Junshi Bio (01877) appoints Zou Jianjun as Executive Director
Zhitong Financial App News, Junshi Bio (01877) issued an announcement that the resolution appointing Zou Jianjun as executive director was approved at the company's 2021 annual general meeting held on June 29th, 2022.
Hong Kong stocks announcement Nuggets | the business impact under the impact of the epidemic is limited. This jewelry sales group announced an annual profit increase of nearly 40%. Goldman Sachs Group will continue to be optimistic about the future!
[headline announcement Nuggets] Liufu Group (00590) released its annual results: profit attributable to shareholders increased by 36.9% over the same period last year, with a final dividend of HK $0.55 per share. Liufu Group announced that as of March 31, 2022, the group had earned HK $11.738 billion, an increase of 32.5% over the same period last year; profit attributable to equity holders was HK $1.392 billion, an increase of 36.9% over the same period last year Basic earnings per share are HK $2.37 and a final dividend of HK $0.55 per share is proposed. Comments: Liufu Group is an investment holding company mainly engaged in jewelry sales.
Junshi Biotouyi (R) (triplet) first-line esophageal cancer indication national listing meeting was successfully held.
Shanghai, June 27 / PRNewswire-Asianet /-- June 25, 2022, the national listing meeting of first-line esophageal cancer indications of Junshi Biological Tuoyi ®(triprizumab injection) was successfully held. This listing will take Guangzhou as the main venue, and set up sub-venues in Beijing, Zhengzhou, Chengdu and Nanjing. Through the interaction between the five cities, we will gather national experts in the field of digestive tract oncology to share and discuss the achievements and prospects of emerging immunotherapy in the field of esophageal cancer, and jointly witness Tuoyi ®(triplizumab) "esophageal squamous cell carcinoma OS17."
Changes in Hong Kong stocks | Junshi Biological H shares rose 11.5%. VV116 industrialization project was approved for filing.
On June 17, 1877.HK shares rose 19% to HK $44.85, or 11.57%, with a total market capitalization of HK $40.85 billion, while the company's A shares rose 5.6% to 85 yuan. According to the online approval and supervision platform for investment projects in Shanghai, recently, the filing of Junshi's VV116 industrialization project was approved by the Zhangjiang Hi-Tech Park Management Committee.
Hong Kong stock changes | Junshi Bio (01877) pulls up more than 8% VV116 industrialization project to be put on record and plans to raise nearly 4 billion for innovative drug research and development.
Zhitong Financial APP learned that Junshi Bio (01877) rose more than 8% in the afternoon and rose 8.33% to HK $43.55 as of press time, with a turnover of HK $76.897 million. According to the news, according to the Securities Times, the online examination and approval supervision platform for investment projects in Shanghai shows that recently, the filing of Junshi's VV116 (deuterium hydrobromide Remidvir tablets) industrialization project was approved by the management committee of Zhangjiang High-tech Park. In addition, Junshi Bio announced that it is proposed to issue up to 70 million A shares, and the total proceeds are expected to be adjusted from the original 3.98 billion yuan to 3.969 billion yuan.
Junshi Bio (01877) adjusts the A-share fixed increase plan to raise no more than 3.969 billion yuan.
Zhitong Financial App News, Junshi Bio (01877) announced that the company held the 12th meeting of the third session of the Board of Directors and the 10th meeting of the third session of the Supervisory Committee on June 14, 2022, deliberating and passing the "motion on adjusting the company's 2022 A-share issuance plan to specific targets" and other related motions. Before adjustment, the total amount of funds raised in this issue (including issuance expenses) shall not exceed 3.98 billion yuan (including capital); after adjustment, the total amount of funds raised in this issue (including issuance expenses)
Shanghai Junshi Biosciences Obtains Approval for Clinical Trial of EGFR Inhibitor Tablets
02:06 AM EDT, 06/14/2022 (MT Newswires) -- Shanghai Junshi Biosciences (HKG:1877) obtained approval from the National Medical Products Administration for the clinical trial of the fourth-generation EG
Announcement selection | GOGOX's initial public offering; Junshi Bio: the fourth generation EGFR inhibitor JS113 clinical trial is approved
Byd Company Limited: yesterday spent 1.035 billion yuan to buy back A shares; Fuhong Hanlin: entered into a license and supply agreement with Organon for HLX11 and HLX14; and Clover-B:SCB-2019 completed the first batch of subjects' vaccination as an III phase trial of allogenic COVID-19 strengthening needle.
Jun Shi Bio (01877.HK): the application for the fourth generation EGFR inhibitor WJ13404 tablets was approved
Recently, Suzhou Junjing Biopharmaceutical Technology Co., Ltd., a subsidiary of the company, received the notice of approval of Drug Clinical Trials approved and issued by the State Drug Administration, and the application for clinical trials of the fourth generation EGFR inhibitor WJ13404 tablets (project code "JS113") was approved.
Loading...
No Stock Yet